Status:
COMPLETED
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
Lead Sponsor:
Naurex, Inc, an affiliate of Allergan plc
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
Eligibility Criteria
Inclusion
- diagnosis of major depressive disorder consistent with DSM-IV-TR
- current episode greater than 8 weeks in duration
- Hamilton Depression score \>/- 21
- less than 25% reduction in depression during current episode assessed by ATRQ
Exclusion
- Axis diagnosis of other psychiatric disorders
- Experiencing hallucinations, delusions, other psychotic symptomatology
- ECT during current episode
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT01234558
Start Date
May 1 2011
End Date
July 1 2012
Last Update
September 12 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mulitple
Evanston, Illinois, United States, 60201